These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30374417)

  • 21. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
    Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
    Liu Z; Lin TM; Purro M; Xiong MP
    ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
    Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in Hypoxia-Inducible Factor-1
    Zhu Y; Chang B; Pang Y; Wang H; Zhou Y
    Tissue Eng Part B Rev; 2023 Aug; 29(4):347-357. PubMed ID: 36475887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K; Sivaramakrishnan G
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferoxamine enhances the regenerative potential of diabetic Adipose Derived Stem Cells.
    Hopfner U; Maan ZN; Hu MS; Aitzetmüller MM; Zaussinger M; Kirsch M; Machens HG; Duscher D
    J Plast Reconstr Aesthet Surg; 2020 Sep; 73(9):1738-1746. PubMed ID: 32418841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Geneen LJ; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
    Ikeda Y; Ozono I; Tajima S; Imao M; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
    PLoS One; 2014; 9(2):e89355. PubMed ID: 24586712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers.
    Alkobtawi M; Sbeih M; Souaid K; Ngô QT; Nassar D; Arbes H; Guillet H; Habibi A; Bartolucci P; Castela M; Aractingi S; Oulès B
    Haematologica; 2023 Jul; 108(7):1920-1933. PubMed ID: 36373248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymeric Nanoparticles Enhance the Ability of Deferoxamine To Deplete Hepatic and Systemic Iron.
    Guo S; Liu G; Frazer DM; Liu T; You L; Xu J; Wang Y; Anderson GJ; Nie G
    Nano Lett; 2018 Sep; 18(9):5782-5790. PubMed ID: 30085676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
    Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
    Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactive Oxygen Species-Triggered Dissociation of a Polyrotaxane-Based Nanochelator for Enhanced Clearance of Systemic and Hepatic Iron.
    Liu Z; Simchick GA; Qiao J; Ashcraft MM; Cui S; Nagy T; Zhao Q; Xiong MP
    ACS Nano; 2021 Jan; 15(1):419-433. PubMed ID: 33378155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
    Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
    Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice.
    Tajima S; Ikeda Y; Sawada K; Yamano N; Horinouchi Y; Kihira Y; Ishizawa K; Izawa-Ishizawa Y; Kawazoe K; Tomita S; Minakuchi K; Tsuchiya K; Tamaki T
    Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E77-86. PubMed ID: 21917632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Barriers to adherence of deferoxamine usage in sickle cell disease.
    Treadwell MJ; Law AW; Sung J; Hackney-Stephens E; Quirolo K; Murray E; Glendenning GA; Vichinsky E
    Pediatr Blood Cancer; 2005 May; 44(5):500-7. PubMed ID: 15602707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.